You just read:

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson's Disease

News provided by

Cognition Therapeutics, Inc. (CogRx)

Sep 29, 2016, 07:30 ET